Disease landscape
Acute myeloid leukemia (AML)
In Visegrad Group (V4) countries, moderate to significant limitations in access to AML diagnosis and treatment have been identified. At the same time, there is considerable variation in results between individual countries: while Slovakia scored 45 points, the remaining countries achieve scores of approximately 60–70 points. The main factor lowering the overall assessment is limited access to new therapies in the V4 region. Despite systemic constraints in the funding of the medicines included in the analysis, the proportion of patients treated with selected therapies remains high. A factor contributing positively to the overall score across all countries is good access to AML diagnostics and relatively short waiting times for reimbursement compared with other diseases.
Cross-Country
General GAP for AML
Compliance with guidelines
Clinical practice guidelines include positive recommendations for 10 medicines used in the treatment of AML. In Slovakia, only 2 of these are publicly funded, whereas in the other countries 4–6 of the recommended therapies are available.
From registration to reimbursement
Population burden
DALY* - Rate per 100k
*disability adjusted life-years
Target population
Selected drugs
Drug access
Number of patients treated (2024)
Drug access
POPULATION treated - selected drugs (%)*
*percentage of the population potentially eligible for treatment with the selected drugs: Rydapt, Venclyxto, Xospata, Tibsovo, Vanflyta
Main issues
- The average time to reimbursement for AML drugs in the V4 countries is 2.8 years. The difference between the shortest and the longest mean time to reimbursement among the countries is 2.5 years.
- The proportion of patients in the target population treated with selected new therapies is relatively high, ranging from over 30% in Slovakia, through 60–65% in Czechia and Hungary, to over 85% in Poland.
- DALY (disability adjusted life-years) burden related to AML in the V4 countries is lower (up to 10%) than the European Union average.
Project
We measured the gap in innovative drug access and diagnostics in selected therapeutic areas in the Visegrád (V4) countries (Poland, Hungary, Czechia and Slovakia).